IL1B and rheumatoid arthritis: The current RA therapies are mainly centered on anti-inflammation strategy aiming at reducing the detrimental effects of pro-inflammatory cytokines such as TNFα, IL-1, and IL-6 in RA, along with the utilization of immune-suppressors and small chemical JAK inhibitors (Firestein and McInnes, 2017).